deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02833766

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial

Sponsor: Swiss Cancer Institute

Conditions Breast Cancer
Interventions anti-EGFR-IL-dox
Updated 17 times since 2017 Last updated: Sep 27, 2021 Started: Oct 28, 2016 Primary completion: Oct 31, 2020 Completion: Aug 3, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

the trial was prematurely terminated as per SAKK board decision from 14th of November 2020. The trial is to be terminated after primary endpoint is reached.

Other terminated trials from Swiss Cancer Institute

See all terminations from Swiss Cancer Institute

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT02833766, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Swiss Cancer Institute, it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Nov 2017 · 10 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jun 2019 · 8 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Aug 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 12 earlier versions

  1. Oct 2021 — Dec 2021 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Feb 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  4. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Nov 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jun 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  9. Oct 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  11. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Swiss Cancer Institute
Data source: Swiss Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Baden, Switzerland , Basel, Switzerland , Bern, Switzerland , Chur, Switzerland , Geneva, Switzerland , Lausanne, Switzerland , Lucerne, Switzerland , Olten, Switzerland , Sankt Gallen, Switzerland and 4 more locations